News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Philogen S.p.A. IPO Pulled as Bayer Corporation Exits Cancer Pact
February 15, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- An eagerly-anticipated initial public offering by the Swiss-Italian biotech Philogen has been cancelled at the last minute after partner Bayer pulled out of their oncology collaboration.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Bayer
MORE ON THIS TOPIC
Mergers & acquisitions
Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations
June 18, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical
June 17, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
A String of Biopharma Deals Has Piqued Analyst Interest in an M&A Return
June 17, 2025
·
3 min read
·
Annalee Armstrong
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
·
2 min read
·
Jef Akst
